Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Total Current Liabilities: 2014-2024

Historic Total Current Liabilities for RedHill Biopharma (RDHL) over the last 10 years, with Dec 2024 value amounting to $22.2 million.

  • RedHill Biopharma's Total Current Liabilities rose 4.96% to $22.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $22.3 million, marking a year-over-year increase of 4.96%. This contributed to the annual value of $22.2 million for FY2024, which is 11.21% up from last year.
  • Per RedHill Biopharma's latest filing, its Total Current Liabilities stood at $22.2 million for FY2024, which was up 11.21% from $20.0 million recorded in FY2023.
  • RedHill Biopharma's Total Current Liabilities' 5-year high stood at $197.5 million during FY2022, with a 5-year trough of $20.0 million in FY2023.
  • In the last 3 years, RedHill Biopharma's Total Current Liabilities had a median value of $22.2 million in 2024 and averaged $79.9 million.
  • As far as peak fluctuations go, RedHill Biopharma's Total Current Liabilities spiked by 589.85% in 2020, and later slumped by 89.88% in 2023.
  • RedHill Biopharma's Total Current Liabilities (Yearly) stood at $73.2 million in 2020, then grew by 11.24% to $81.5 million in 2021, then spiked by 142.36% to $197.5 million in 2022, then crashed by 89.88% to $20.0 million in 2023, then climbed by 11.21% to $22.2 million in 2024.